Mechanism of Action
ErbB Receptor Signaling
NRG-1 binds to ErbB3 or ErbB4 receptors, which then heterodimerize with ErbB2 (HER2) to activate downstream signaling cascades. In cardiomyocytes, ErbB2/ErbB4 activation stimulates the PI3K/Akt pathway, promoting cell survival and hypertrophic adaptation. The MAPK/ERK pathway is also activated, supporting cell proliferation and protein synthesis. ErbB4 signaling in cardiomyocytes specifically promotes mitochondrial biogenesis and metabolic efficiency.
Cardiac Regeneration and Protection
NRG-1 promotes cardiomyocyte proliferation in neonatal and adult hearts, representing one of the few endogenous signals capable of stimulating adult cardiomyocyte division. It also reduces cardiomyocyte apoptosis during ischemia, improves mitochondrial function, and promotes beneficial cardiac remodeling. In failing hearts, NRG-1 restores sarcomeric protein expression, improves calcium handling, and reverses pathological hypertrophy.
Neuromuscular and CNS Effects
At neuromuscular junctions, NRG-1 regulates acetylcholine receptor clustering and synaptic maintenance. In the CNS, NRG-1/ErbB4 signaling is critical for GABAergic interneuron function and schizophrenia-associated pathways. GGF2 isoforms promote Schwann cell survival and myelination, making NRG-1 a target in peripheral nerve repair and demyelinating disease research.
Research Summary
Heart Failure (Phase II)
ClinicalMultiple Phase II trials (NRGO, CHORD) tested rhNRG-1 in chronic heart failure with reduced ejection fraction (HFrEF). Results showed improvements in left ventricular ejection fraction (LVEF), 6-minute walk test, and NT-proBNP reduction. The CHORD trial (recombinant NRG-1) demonstrated sustained benefit at 90 days after a 10-day infusion course. Phase III planning is underway for select programs.
Neuroprotection
PreclinicalGGF2 (NRG-1 isoform) reduced infarct volume and improved functional outcomes in rodent stroke and TBI models. Mechanisms include reduced neuroinflammation, improved oligodendrocyte survival, and enhanced remyelination. NRG-1 deficiency in mouse models accelerates neurodegeneration, supporting an endogenous neuroprotective role.
Neuromuscular Disease
PreclinicalIn ALS, muscular dystrophy, and peripheral neuropathy models, NRG-1 preserves neuromuscular junction integrity and delays denervation atrophy. ErbB2/ErbB4 activation maintains Schwann cell populations that are critical for axonal support and remyelination after nerve injury.
Calculate your Neuregulin-1 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Heart failure (clinical) | 0.6-1.2 mcg/kg/day IV | Once daily x 10 days | IV infusion over 10 hours |
| Cardioprotection | 100 ng/kg/day IV | Daily x 5 days | IV (preclinical) |
| Neuroprotection (GGF2) | 2-10 mg/kg IV | Post-injury dosing | IV (preclinical) |
Clinical dosing from Phase II HF trials. GGF2 doses from preclinical models only.
Interactions
Safety Profile
In Phase II trials, rhNRG-1 was generally well tolerated. Most common adverse effects included infusion-related reactions (flushing, bradycardia), reversible with rate adjustment. Transient asymptomatic drops in blood pressure occurred in some subjects. Given ErbB2 involvement in HER2-positive cancers, careful monitoring is required in oncology patients or those with HER2-positive tumors. No significant long-term safety signals emerged in cardiac trials.
References
- [1]Ky B, et al. rhNRG-1 in heart failure: NRGO trial. JACC Heart Fail. 2015.
- [2]Gao R, et al. A randomized clinical trial of rhNRG-1 (CHORD). J Am Coll Cardiol. 2010.
- [3]Odiete O, et al. Neuregulin in cardiovascular development and disease. Circ Res. 2012.